Sign In
Buy GLP
$48.63
+0.410 (+0.85%)
At Close: Jul 28, 2026
Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock?
12:15pm, Saturday, 20'th Jun 2026
Novo Nordisk was the first to market with a GLP-1 weight-loss drug. It lost its early lead to Eli Lilly, which is now the name to beat in the GLP-1 race.
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
08:45am, Saturday, 20'th Jun 2026
The GLP-1 revolution is quietly continuing even as investor interest has moved on to more timely topics. One of the best ways to access the fast-growing weight loss drug space is via makers like Novo
Is Global Partners (GLP) Stock Undervalued Right Now?
10:41am, Friday, 19'th Jun 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Filed applications include claims directed to the use of EL-22 and EL-32 for preserving lean muscle mass during GLP-1 and obesity-related weight loss Filed applications include combination and co-admi
Ozempic Linked To Lower Risk Of Violence In New Study
11:45am, Wednesday, 17'th Jun 2026
The researchers said the findings are not causal and urged more research into whether GLP-1s reduce the risk of violence. Daniel Semenza, lead author of the study and director of research at the New J
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
09:25am, Wednesday, 17'th Jun 2026
More People Than Ever Taking GLP-1 Drugs for Weight Loss Growing List of Diseases Now Indicated as Treatable With GLP-1 Drugs KELOWNA, BC / ACCESS Newswire / June 17, 2026 / Lexaria Bioscience Corp. (
GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand
09:25am, Wednesday, 17'th Jun 2026
More people than ever taking GLP-1 drugs for weight loss Growing list of diseases now indicated as treatable with GLP-1 drugs
Matricelf Advances Toward First in Human Trial Following Successful GLP Safety Study Completion
07:00am, Wednesday, 17'th Jun 2026
TEL AVIV, Israel, June 17, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing personalized engineered tissue implants for spinal cord injury, today announced
Why People are Drinking Less & GLP-1 Drug Impact on Alcohol Consumption
04:30pm, Monday, 15'th Jun 2026
Marten Lodewijks, managing director and president of IWSR, breaks down what's behind the decline in global alcohol consumption. He discusses how emerging markets are impacting overall consumption tren
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow
08:15am, Sunday, 14'th Jun 2026
Sales of Eli Lilly's GLP-1 drugs are growing very quickly. Eli Lilly continues to innovate in the competitive GLP-1 space.
Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK
11:03am, Thursday, 11'th Jun 2026
Approval is based on results from the OASIS 4 trial, which investigated semaglutide tablets 25 mg in adults living with obesity and overweight versus placebo in addition to diet and exercise Semagluti
The GLP-1 stock nobody is pricing in isn't a drugmaker
09:30am, Thursday, 11'th Jun 2026
Scott Galloway and Ed Elson laid out the math on Prof G Markets and it should make every fast food shareholder uneasy: roughly 30 million Americans, about 1 in 8 US adults, are now on GLP-1s, and the
Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases
06:03am, Thursday, 11'th Jun 2026
Some employers are planning to drop coverage of GLP-1 drugs for weight loss next year as more people take the medications, counteracting some savings from lower prices for Novo Nordisk's Wegovy and El
2 Highly Ranked Stocks to Consider After May's Hot CPI Report: DOW, GLP
03:21pm, Wednesday, 10'th Jun 2026
With inflation pressures resurfacing and commodity markets reacting to geopolitical developments, Dow Inc. and Global Partners may be well positioned to navigate the current environment.
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
01:01pm, Wednesday, 10'th Jun 2026
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
